- Home
- COOT vs TENX Comparison
COOT vs TENX Comparison
Compare COOT & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COOT
- TENX
- Stock Information
- Founded
- COOT 2020
- TENX 1967
- Country
- COOT Australia
- TENX United States
- Employees
- COOT N/A
- TENX N/A
- Industry
- COOT
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- COOT
- TENX Health Care
- Exchange
- COOT NYSE
- TENX Nasdaq
- Market Cap
- COOT 23.0M
- TENX 21.7M
- IPO Year
- COOT N/A
- TENX N/A
- Fundamental
- Price
- COOT $1.25
- TENX $6.75
- Analyst Decision
- COOT
- TENX Strong Buy
- Analyst Count
- COOT 0
- TENX 4
- Target Price
- COOT N/A
- TENX $20.67
- AVG Volume (30 Days)
- COOT 14.6K
- TENX 53.9K
- Earning Date
- COOT 01-01-0001
- TENX 03-27-2025
- Dividend Yield
- COOT N/A
- TENX N/A
- EPS Growth
- COOT N/A
- TENX N/A
- EPS
- COOT N/A
- TENX N/A
- Revenue
- COOT $23,793,673.00
- TENX N/A
- Revenue This Year
- COOT N/A
- TENX N/A
- Revenue Next Year
- COOT N/A
- TENX N/A
- P/E Ratio
- COOT N/A
- TENX N/A
- Revenue Growth
- COOT 16.10
- TENX N/A
- 52 Week Low
- COOT $0.61
- TENX $2.77
- 52 Week High
- COOT $10.00
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- COOT 46.64
- TENX 51.52
- Support Level
- COOT $1.22
- TENX $6.10
- Resistance Level
- COOT $1.57
- TENX $7.69
- Average True Range (ATR)
- COOT 0.14
- TENX 0.53
- MACD
- COOT -0.01
- TENX -0.07
- Stochastic Oscillator
- COOT 27.48
- TENX 44.12
About COOT AUSTRALIAN OILSEEDS HOLDINGS LTD
Australian Oilseeds Holdings Ltd through its subsidiaries, is focused on the manufacture and sale of chemical-free, non-GMO, sustainable edible oils and products derived from oilseeds. The company believes that transitioning from a fossil fuel economy to a renewable and chemical-free economy is the solution to many health problems the world is facing presently.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.